niacinamide has been researched along with Bilateral Wilms Tumor in 2 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib, 200 mg/m(2) /dose, was administered every 12 hr continuously for 28 day cycles using a two-stage design in two primary strata (rhabdomyosarcoma and Wilms tumor) and two secondary strata (HCC and PTC)." | 5.20 | Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group. ( Blaney, SM; Fox, E; Jayaprakash, N; Kim, A; Krailo, M; Weigel, B; Widemann, BC, 2015) |
| " In a study evaluating the combination of sorafenib, bevacizumab, and low-dose cyclophosphamide in children with solid tumors, an unexpectedly high incidence of pneumothorax was observed." | 3.81 | Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors. ( Davidoff, AM; Interiano, RB; McCarville, MB; Navid, F; Sandoval, J; Wu, J, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Interiano, RB | 1 |
| McCarville, MB | 1 |
| Wu, J | 1 |
| Davidoff, AM | 1 |
| Sandoval, J | 1 |
| Navid, F | 1 |
| Kim, A | 1 |
| Widemann, BC | 1 |
| Krailo, M | 1 |
| Jayaprakash, N | 1 |
| Fox, E | 1 |
| Weigel, B | 1 |
| Blaney, SM | 1 |
1 trial available for niacinamide and Bilateral Wilms Tumor
| Article | Year |
|---|---|
Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; | 2015 |
1 other study available for niacinamide and Bilateral Wilms Tumor
| Article | Year |
|---|---|
Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Bevacizumab; Bone Neoplasms; Child; Child, Preschool; Fe | 2015 |